Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
0.9002
Dollar change
+0.0502
Percentage change
5.91
%
IndexRUT P/E- EPS (ttm)-1.21 Insider Own15.01% Shs Outstand68.49M Perf Week6.76%
Market Cap65.53M Forward P/E- EPS next Y-1.14 Insider Trans0.00% Shs Float61.87M Perf Month11.84%
Income-87.79M PEG- EPS next Q-0.38 Inst Own65.11% Short Float4.93% Perf Quarter2.30%
Sales7.00M P/S9.36 EPS this Y-34.25% Inst Trans4.53% Short Ratio4.64 Perf Half Y-38.76%
Book/sh2.97 P/B0.30 EPS next Y16.12% ROA-31.69% Short Interest3.05M Perf Year-85.78%
Cash/sh3.00 P/C0.30 EPS next 5Y- ROE-35.17% 52W Range0.67 - 6.43 Perf YTD-4.98%
Dividend Est.- P/FCF- EPS past 5Y-17.80% ROI-37.73% 52W High-86.00% Beta0.43
Dividend TTM- Quick Ratio13.83 Sales past 5Y0.00% Gross Margin100.00% 52W Low33.44% ATR (14)0.05
Dividend Ex-Date- Current Ratio13.83 EPS Y/Y TTM-19.14% Oper. Margin-1384.97% RSI (14)53.60 Volatility5.98% 6.33%
Employees84 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin-1254.16% Recom1.80 Target Price11.67
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q-28.50% Payout- Rel Volume1.69 Prev Close0.85
Sales Surprise4099.16% EPS Surprise10.24% Sales Q/Q- EarningsNov 13 AMC Avg Volume656.68K Price0.90
SMA200.96% SMA501.99% SMA200-40.07% Trades Volume1,108,481 Change5.91%
Date Action Analyst Rating Change Price Target Change
Aug-11-23Downgrade Wells Fargo Overweight → Equal Weight $4
Mar-16-23Downgrade William Blair Outperform → Mkt Perform
Dec-08-21Initiated Wells Fargo Overweight $19
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Feb-02-24 05:37AM
Dec-18-23 08:51AM
Nov-21-23 04:01PM
Nov-13-23 04:01PM
Nov-03-23 04:03PM
12:30PM Loading…
Oct-24-23 12:30PM
Oct-23-23 10:08AM
Oct-09-23 05:56PM
Oct-04-23 09:32AM
Oct-03-23 04:10PM
Sep-20-23 06:30PM
Aug-31-23 04:01PM
Aug-10-23 04:01PM
Aug-04-23 04:03PM
Jul-07-23 04:01PM
04:01PM Loading…
Jun-09-23 04:01PM
May-31-23 07:00AM
May-11-23 04:01PM
Apr-05-23 04:01PM
Mar-14-23 04:01PM
Mar-13-23 07:00AM
Mar-06-23 07:00AM
Mar-03-23 06:17PM
Mar-01-23 04:01PM
Feb-06-23 04:01PM
11:44AM
Jan-26-23 06:44AM
Jan-13-23 04:01PM
Jan-06-23 07:04AM
Jan-04-23 04:01PM
04:01PM Loading…
Dec-07-22 04:01PM
Nov-14-22 07:00AM
Nov-11-22 04:01PM
Nov-10-22 04:01PM
Nov-09-22 04:01PM
Nov-03-22 10:00AM
Oct-14-22 07:00AM
Oct-06-22 04:01PM
Oct-03-22 04:01PM
Sep-29-22 04:05PM
Sep-02-22 04:30PM
Sep-01-22 07:00AM
Aug-30-22 12:10PM
Aug-11-22 04:01PM
Aug-03-22 04:30PM
Jul-18-22 09:55AM
Jul-11-22 04:30PM
Jul-08-22 02:42PM
Jul-07-22 04:30PM
Jul-06-22 04:30PM
Jun-30-22 01:08PM
09:55AM
Jun-28-22 03:57PM
11:58AM
10:23AM
09:58AM
Jun-27-22 09:31PM
04:01PM
11:46AM
Jun-10-22 09:35AM
Jun-03-22 04:30PM
Jun-01-22 06:15AM
May-23-22 09:55AM
09:35AM
May-12-22 04:01PM
May-11-22 09:32AM
08:59AM
May-10-22 08:38AM
May-05-22 04:30PM
May-04-22 03:57PM
05:57AM
May-03-22 04:01PM
Apr-15-22 04:05PM
Apr-05-22 07:00AM
Mar-24-22 11:03AM
Mar-23-22 04:58PM
Mar-18-22 12:42PM
Mar-17-22 04:01PM
Mar-02-22 07:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 07:00AM
Dec-09-21 06:05PM
Dec-08-21 09:38AM
Nov-16-21 12:07PM
11:38AM
07:27AM
06:02AM
Nov-15-21 04:05PM
Nov-11-21 07:00AM
Nov-10-21 09:47AM
Nov-09-21 04:05PM
Nov-03-21 08:00AM
Oct-27-21 08:00AM
Oct-25-21 10:33AM
Oct-15-21 02:12PM
Oct-05-21 04:01PM
Sep-21-21 02:34PM
Sep-02-21 07:00AM
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kirk Christopher J.DirectorJul 20Option Exercise0.9048,95044,055431,348Jul 24 04:20 PM